Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 10/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617403 | 0.85 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL962517 | 0.82 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1039865 | 0.81 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nitric Acid SCHEMBL1617375 | 0.80 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nitric Acid SCHEMBL1617470 | 0.80 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nitric Acid SCHEMBL1617372 | 0.80 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4255987 | 0.80 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1041288 | 0.80 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1040004 | 0.78 | PTK2 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL966637 | 0.77 | KDM4E (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910142-B | Modulators for beta-amyloid | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | disclosed |
| WO-2012030952-A3 | REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY | TEXAS INSTRUMENTS INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2231629-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| CN-101910142-A | The conditioning agent of amyloid beta | HOFFMANN LA ROCHE | 2010-12-08 | — | — | CN | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | PSEN1 2/4885PSEN2 6/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.